Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

120 results about "Encephalomyelitis" patented technology

Encephalomyelitis is inflammation of the brain and spinal cord.

B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome

The present invention relates in a first aspect to a B-cell depleting anti-CD20 antibody or a CD20-binding antibody fragment thereof for the treatment of chronic fatigue syndrome and myalgic encephalomyelitis. In particular, the present invention relates to the use of anti-CD20 monoclonal antibodies or fragments thereof which are preferably humanized for the treatment of chronic fatigue syndrome / myalgic encephalomyelitis in a subject afflicted with said disease.
Owner:BERGEN TEKNOLOGIOVERFORING

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
Owner:AMGEN INC

New conopeptide, medicinal composition and uses thereof

The invention belongs to the fields of biochemistry and molecular biology, relates to a new conopeptide, and a medicinal composition, a preparation method and uses thereof, also relates to a nucleic acid construct, an expression vector of the nucleic acid construct, a converted cell of the expression vector and a fusion protein of the conopeptide, and further relates to a method for blocking out an acetylcholine receptor, and pharmaceutical uses of the conopeptide. The new conopeptide K41JM and analogs thereof can specifically block out the acetylcholine receptor (nAChRs) (such as alpha9alpha10nAChR), have can treat neuralgia, cancer chemotherapy, breast cancer, lung cancer, wound healing, encephalomyelitis, epilepsy and ischaemia, and have good application prospects in the preparation of pain easing medicines, anticancer medicines and neuroscience tool medicines.
Owner:HAINAN UNIVERSITY

Heterocyclic compounds and their uses

InactiveUS20130096134A1BiocideSenses disorderDiseaseB-cell acute lymphoblastic leukaemia
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
Owner:AMGEN INC

Avian Encephalomyelitis virus attenuated vaccine strain

The invention provides an Avian Encephalomyelitis virus YBF02 strain. The strain, with a preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 8505, is preserved in China General Microbiological Culture Collection Center on November 8, 2013 at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. The Avian Encephalomyelitis virus attenuated vaccine strain screened according the invention is subjected to continuous passage in a chicken body by horizontal transmitted infection, and no virulence return phenomenon occurs, therefore, the strain is stable in hereditary, and accords with the standard of no virulence return of Avian Encephalomyelitis virus attenuated vaccine strains; prepared vaccines can provide effective immune protection, and have a good commercial development prospect.
Owner:YEBIO BIOENG OF QINGDAO

Swine Hemagglutinating encephalomyelitis virus colloidal gold antigen detecting test paper and preparing method thereof

The present invention relates to a novel technique-colloidal gold immunochromatography for quickly detecting the Swine Hemagglutinating encephalomyelitis virus (HEV), and to a test paper which is prepared by the technique for preparing the Swine Hemagglutinating encephalomyelitis virus. The invention develops a monoclonal antibody (Ab1) of the Swine Hemagglutinating encephalomyelitis virus and a monoclonal antibody (Ab2) of rabbit anti- Swine Hemagglutinating encephalomyelitis virus. The Ab1 labeled colloidal gold is taken as the gold-labeled antibody and the Ab2 is taken as the catching antibody. The normal anti-mouse IgG antibody is used as a quality control antibody. The materials of antibody, cellulose nitrate film (NC film), combining pad, sample pad, back lining, plastic card, etc. are processed and assembled to the test paper. The test paper can detect the Swine Hemagglutinating encephalomyelitis virus in the sickened pig brain tissue and the feces. The technique of the invention has the characteristics of simple operation, high speed, excellent sensitivity, excellent specificity, etc. Furthermore the technique of the invention is especially suitable for the clinic sample detection of disease appearance field, clinic, places with no available experiment condition, etc.
Owner:JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products